Acambis rated at hold by Jefferies

Jefferies & Co., Inc. analyst Robin Campbell gave Acambis plc a hold rating based on lower revenue guidance and an expected increase in research and development spending. The company is also faced with a lack of partnering prospects and government contract delays related to the smallpox vaccine. Shares of the Cambridge, United Kingdom-based pharmaceutical company were down 5.50p, or 3.58%, at 148.00p on volume of 1,548,606 shares versus the three-month running average of 529,349 shares. (LSE: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.